Humoral anti-SARS-CoV-2 immune response for different strains after Sinovac-CoronaVac and Oxford/AstraZeneca (ChAdOx1-S) full vaccination on a healthcare population in Brazil

Journal Title: Revista Uningá - Year 2024, Vol 61, Issue 1

Abstract

COVID-19, caused by the SARS-CoV-2 virus, is a global respiratory syndrome with high mortality rates. Vaccination is currently the only proven method to prevent the disease, although the role of lab data in assessing efficacy remains uncertain. This study aimed to assess spike-binding and neutralizing antibody levels following full vaccination with Oxford/AstraZeneca (ChAdOx1 nCoV-19) or CoronaVac in healthcare workers in southeastern Brazil. ChAdOx1 nCoV-19 and CoronaVac induced IgG antibodies against trimeric spike glycoproteins in 99.5% and 80.9% of individuals, respectively. Neutralizing antibodies were produced against two viral strains groups: variants group 1 (Wuhan-Hu-1, Alpha) and variants group 2 (Beta, Gamma) with neutralization rates of 88.3% and 78.2% for ChAdOx1 nCoV-19, and 68.1% and 48.9% for CoronaVac. No associations were found between neutralizing levels and comorbidities, age, or side effects. A positive correlation was observed between IgG antibody concentrations against trimeric spike glycoproteins and neutralizing levels for both vaccines and variants. These findings indicate that both vaccines induced reasonable levels of neutralizing antibodies against variants group 1, but only ChAdOx1 nCoV-19 maintained acceptable levels against a variant strain. The study suggests that evaluating vaccine responses to different pathogen strains can aid in managing healthcare workforce concerns and improve vaccine selection, thereby enhancing overall vaccination strategies.

Authors and Affiliations

Maicon Jeferson Silva de Oliveira, Beatriz Birelli do Nascimento, Fernanda de Assis Oliveira, Mahelly Bueno de Almeida, Márcio Rodrigues, Flavia Cristina Cardoso Carvalho, Éric Diego Barioni, Rodrigo Azevedo Loiola, Rômulo Tadeu Dias de Oliveira, Gustavo Henrique Oliveira da Rocha

Keywords

Related Articles

Atrophic mandible fracture approach by load-bearing system: case report

Mandible fractures are the most frequent in the maxillofacial complex. Due to weakness and impaired reflexes, 10.1% to 56% of affected individuals are elderly. Thus, this study aimed to report a case report of a mandibul...

Knowledge and precautions of light-curing composite resin restorations by dental students

Composite resin is versatile material for performing several dental procedures in dentistry, and its use has already been consolidated in this field. The clinical success of adhesive restorations is directly related to t...

A therapeutic alternative for posterior cross bite in adult patients: MARPE

Transverse maxillary deficiency is characterized as a malocclusion that affects patients of all age groups. Rapid maxillary expansion (RME) is indicated for its correct treatment. However, there are cases in which therap...

Artificial sweeteners: regulation in Brazil, technological implications in food production and health

Sweeteners provide a sweet taste to foods and are used to replace sucrose and reduce caloric value. Acesulfame potassium, aspartame, sodium cyclamate, saccharin, sucralose and neotame are the artificial sweeteners regula...

Access of hypertensive patients to dental care in Primary Health Care in Palmas, TO

Systemic Arterial Hypertension (SAH) is a highly prevalent pathology in the Brazilian population and requires significant efforts from primary healthcare units, serving as the gateway to the Unified Health System (SUS) a...

Download PDF file
  • EP ID EP732441
  • DOI 10.46311/2318-0579.61.eUJ4570
  • Views 48
  • Downloads 0

How To Cite

Maicon Jeferson Silva de Oliveira, Beatriz Birelli do Nascimento, Fernanda de Assis Oliveira, Mahelly Bueno de Almeida, Márcio Rodrigues, Flavia Cristina Cardoso Carvalho, Éric Diego Barioni, Rodrigo Azevedo Loiola, Rômulo Tadeu Dias de Oliveira, Gustavo Henrique Oliveira da Rocha (2024). Humoral anti-SARS-CoV-2 immune response for different strains after Sinovac-CoronaVac and Oxford/AstraZeneca (ChAdOx1-S) full vaccination on a healthcare population in Brazil. Revista Uningá, 61(1), -. https://europub.co.uk/articles/-A-732441